STAT3 has emerged as a promising drug target, and anti-STAT3 agents have demonstrated promising therapeutic activity across cancer models including non-small cell lung cancer (NSCLC), mismatch repair-deficient colorectal cancer (MRD CRC) and pancreatic adenocarcinoma (PDAC).6, 9 Parallel to STAT3-mediated immune suppression exist other pathways including PD-1/PD-L1, a clinically relevant pathway that produces multiple inhibitor signals including T cell inhibition. This evidence concerns the gene CD274 and non-small cell lung carcinoma.